Medtronic MiniMed, Inc. manufactures insulin pumps and glucose monitoring systems. Its products include minimed 530g system, smartguard, enlite sensor, minimed revel and infusion sets. The company was founded by Alfred E. Mann in 1979 and is headquartered in Northridge, CA.

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Part of Danone SA, Nutricia NV is a Dutch company located in Zoetermeer that manufactures dry, condensed and evaporated dairy products.

Gelesis is a clinical stage biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients. Gelesis100, our lead product, is an orally- administered smart pill which is constructed of materials that are General Recognized as Safe (GRAS) by the Food and Drug Administration (FDA). Each Gelesis100 capsule contains thousands of hydrogel particles approximately the size of a grain of salt that expand to 100 times their dry weight. The pill is designed to act mechanically in the stomach and small intestine to increase satiety and decrease hunger, resulting in reduced caloric intake and weight loss. <a href="http://www.gelesis.com/">Gelesis</a> was founded in 2006 in Boston, Massachusetts

Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. Its product pipelines include: Biochaperone Lispro, Combo, M1pram, Glucagon, Gla Glp-1, Glucagon Glp-1 & Cell Therapy. The company was founded by Gérard Soula, Olivier Soula and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.

Part of Becton, Dickinson & Co., Becton, Dickinson & Co. Ltd. is an Irish company located in Dublin. The firm manufactures and supplies medical devices.

MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Westlake Village, California, the company was founded in February 1991. However, its present form is a result of a 2003 merger of three companies owned by Alfred E. Mann, Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing a allergy vaccine technology. MannKind Corporation was named after its founder, Alfred Mann. One of the former companies, Pharmaceutical Discovery, was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).

Sanpu Pharmaceutical Co. Ltd., part of Tibet Rongen Technology Co. Ltd., is a Chinese company located in Xining. The firm manufactures pharmaceutical products. It was acquired by Kunming Yuxin Pharmaceutical Merging Investment Center LP from Far East Smarter Energy Co., Ltd.

Nanjing Children's Hospital Ltd. is a Chinese private company located in Nanjing that provides healthcare services.

Baolingbao Biology Co., Ltd. engages in the manufacture of all kinds functional sugar. Its products are categorized into prebiotics, sugar alcohols and new sugar, dietary fiber, starch and modified starch, starch sugar, and animal nutrition. The company was founded on October 16, 1997 and is headquartered in Dezhou, China.

Beijing Factor Health Technology Co., Ltd., established on 2015-04-09, Business scope includes technology development,Technology Promotion,technology transfer,technical consulting,Technical Services;computer technology training;Economic and Trade Consulting;Computer System Services;Basic software service;Application software service;data processing(Bank Card Center in Data Processing,PUEvalue in1.4Except for the above cloud computing data centers);computer repair;buisness planning;design,make,acting,Place an ad;Conference Services;market survey;Undertake exhibition and display activities;Organize cultural and artistic exchange activities(Does not include commercial performances);Photographic Printing Services;computer animation design;investment management;Investment Advisory;Educational Consulting;software development;product design;Sales of machinery and equipment,Wujinjiaodian,metallic material,building materials,electronic product,computer,Software and Auxiliary Equipment,communication equipment,Edible produce,clothing,shoes and hats,Toy,hygiene products,cosmetic,sporting goods,Contraceptives,crafts,jewelry,Groceries,medical instrumentsIkind,Class II Medical Devices,stationery;health management,Health Advisory(Except for medical treatment activities subject to approval);Medical Research and Experimental Development;Sales of Class III Medical Devices;sell food;retail medicine;Internet information service;HR Services;operating telecommunications business.(Market entities independently choose business projects in accordance with the law,Carry out business activities;operating telecommunications business,Internet information service,retail medicine,sell food,Human resources services and projects subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

NeurMedix, Inc. is a private company headquartered in San Diego, CA, that operates as a biopharmaceutical company which develops neurological and neuro-degenerative products. The firm was founded by Terren S. Peizer, he is the current CEO of the firm.\nThe company says this about itself: NeurMedix, Inc. is a clinical-stage biopharmaceutical company that engages in developing products for the treatment of neurological and neuro-degenerative disorders and certain cancers. The company��s new drug candidate has successfully completed 11 pre-clinical, and 6 Phase 1, Phase 1/2, and Phase 2 clinical studies in various inflammatory diseases indicating its broad effect in inhibiting inflammatory cascade without evidence of immunosuppression. In addition to Alzheimer��s Disease, NeurMedix plans to enter clinical trials for the treatment of Parkinson��s Disease and several oncological indications. The company��s focus is on diseases with significant unmet medical needs and commercial potential in order to expedite FDA review, minimize capital requirements and optimize shareholder value.

Harbor Therapeutics, Inc. is the world leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals and potential nutraceuticals for human health. The adrenals, triangular glands located above each kidney, produce among other key components of the human metabolome, dozens of steroid hormones and have yielded some of the most successful pharmaceuticals.

BioVie is pioneering an innovative therapeutic approach targeting ascites due to liver cirrhosis. Ascites, or the accumulation of fluid in the abdomen, is the most common complication of cirrhosis due to NASH (non-alcoholic steatohepatitis), alcoholic liver disease and/or hepatitis C. Ascites affects about 100,000 Americans and many times more worldwide, and contributes substantially to mortality. Our therapy BIV201 is based on a drug that is not yet available in the US but is approved in about 50 countries to treat related complications of liver cirrhosis. The Company, formerly knows as NanoAntibiotics, Inc., recently acquired LAT Pharma LLC. This merger provided our lead development program, BIV201. Following a pre-investigational new drug meeting (“pre-IND”) with the FDA in early 2016, the Company is now assembling its IND package, and may commence a US clinical trial as early as 2017.

LSI Medience Corp. engages in the clinical examination business. It also engages in the diagnostic agent and drug discovery support business. The company was founded on April 1, 2014 and is headquartered in Tokyo, Japan.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

American Home Products LLC operates as a holding company which engages in the acquisition of niche manufacturers and distributors of functional and decorative architectural building and renovation products. These products are provided to the residential markets. The company was founded in 2014 and is headquartered in Van Nuys, CA.

Markets and distributes specialty, artisanal and farmstead cheese products